Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Carr's Group enters manufacturing partnership with Vetalis

(Sharecast News) - Carr's Group announced a strategic manufacturing partnership with French animal health company Vétalis on Friday, to develop an enhanced range of Tracesure boluses, with distribution due to begin in autumn 2025. The London-listed firm said the move followed its decision to close its ANIMAX production facility in June, allowing it to shift resources towards innovation and growth in livestock nutrition.

It said the partnership was expected to deliver operational savings while maintaining Tracesure's leading position in the UK and Irish markets.

Vétalis, a specialist in precision bolus supplementation, would support Carr's in developing new science-backed formulations aimed at improving animal health and supporting sustainable farming practices.

Carr's said the collaboration would support its strategy of boosting on-farm productivity and addressing global food security challenges.

The combination of Vétalis' manufacturing expertise and Carr's nutrition capabilities was intended to drive innovation, improve efficiency, and enhance product delivery.

"This is a key strategic milestone as we reposition the Group as a focused, pure-play agriculture business," said chief executive officer Joshua Hoopes

"Partnering with Vétalis enables us to build a more efficient platform for sustainable growth, while strengthening our customer offering and creating long-term value for shareholders."

At 1307 BST, shares in Citywire were up 5.53% at 146.18p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.